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The expression and activity of the epidermal growth factor receptor (EGFR) are determinants of radiosensitivity in several tumour
types, including non-small cell lung cancer (NSCLC). However, little is known of whether genetic alterations of EGFR in NSCLC cells
affect the therapeutic response to monoclonal antibodies (mAbs) to EGFR in combination with radiation. We examined the effects
of nimotuzumab, a humanised mAb to EGFR, in combination with ionising radiation on human NSCLC cell lines of differing EGFR
status. Flow cytometry revealed that H292 and Ma-1 cells expressed high and moderate levels of EGFR on the cell surface,
respectively, whereas H460, H1299, and H1975 cells showed a low level of surface EGFR expression. Immunoblot analysis revealed
that EGFR phosphorylation was inhibited by nimotuzumab in H292 and Ma-1 cells but not in H460, H1299, or H1975 cells.
Nimotuzumab augmented the cytotoxic effect of radiation in H292 and Ma-1 cells in a clonogenic assay in vitro, with a dose
enhancement factor of 1.5 and 1.3, respectively. It also enhanced the antitumor effect of radiation on H292 and Ma-1 cell xenografts
in nude mice, with an enhancement factor of 1.3 and 4.0, respectively. Nimotuzumab did not affect the radioresponse of H460 cells in
vitro or in vivo. Nimotuzumab enhanced the antitumor efficacy of radiation in certain human NSCLC cell lines in vitro and in vivo. This
effect may be related to the level of EGFR expression on the cell surface rather than to EGFR mutation.
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Epidermal growth factor receptor (EGFR) is a receptor tyrosine
kinase that is abnormally upregulated and activated in a variety of
tumours (Baselga, 2002). Deregulation of receptor tyrosine kinases
as a result of overexpression or activating mutations is frequently
associated with human cancers and leads to the promotion of
cell proliferation or migration, inhibition of cell death, or the
induction of angiogenesis (Gschwind et al, 2004). The epidermal
growth factor receptor has thus been identified as an important
target in cancer therapy (Baselga and Arteaga, 2005). Several
agents, including small-molecule inhibitors of the tyrosine kinase
activity of EGFR (EGFR-TKIs) and monoclonal antibodies (mAbs)
specific for EGFR, have been designed to block EGFR signalling
selectively (Ettinger, 2006; Harari and Huang, 2006; Imai and
Takaoka, 2006). Among EGFR-TKIs, gefitinib and erlotinib have
been extensively evaluated in non-small cell lung cancer (NSCLC),
and sensitivity to these drugs has been associated with the
presence of somatic mutations in the EGFR kinase domain or with
EGFR amplification (Lynch et al, 2004; Paez et al, 2004; Pao et al,
2004; Cappuzzo et al, 2005; Mitsudomi et al, 2005; Takano et al,
2005). Various mAbs to EGFR are also undergoing preclinical and
clinical trials of their efficacy as anticancer agents. However,
biological markers able to predict the response to such antibodies
have remained elusive.
The possibility of combining chemotherapy or radiation therapy
with anti-EGFR mAb treatment has generated much interest,
because the cellular targets for these agents and their mechanisms
of action are different (Baumann and Krause, 2004). Studies have
thus been undertaken to determine whether inhibition of EGFR
signalling improves the response to chemotherapy or radiation
therapy. Preclinical studies have shown that the anti-EGFR mAb
cetuximab markedly increases the cytotoxic effect of chemotherapy
or radiation therapy in various EGFR-expressing tumour cell lines
(Huang et al, 1999; Milas et al, 2000; Buchsbaum et al, 2002;
Prewett et al, 2002; Raben et al, 2005; Ettinger, 2006). A phase III
clinical trial also showed that the combination of cetuximab with
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sradiation therapy resulted in a significant improvement in local
control and survival compared with radiation therapy alone,
without an increase in radiation-induced side effects, in patients
with locally advanced head and neck cancer (Bonner et al, 2006).
Nimotuzumab (also known as h-R3) is a humanised anti-EGFR
mAb, which is currently undergoing clinical evaluation. In a
preclinical study, nimotuzumab showed marked antiproliferative,
proapoptotic, and antiangiogenic effects in tumours that overexpress
EGFR (Crombet-Ramos et al, 2002). In early clinical trials,
nimotuzumab has shown a longer half-life and a greater area
under the curve (AUC) in comparison with other anti-EGFR
antibodies (Crombet et al, 2003). A phase I/II trial showed that
nimotuzumab was well tolerated and enhanced the curative
potential of radiation in patients with advanced head and neck
cancer (Crombet et al, 2004). Given that little is known of the
antitumor action of nimotuzumab in NSCLC, we investigated the
growth-inhibitory effects of this mAb alone and in combination
with radiation in NSCLC cell lines with differing patterns of EGFR
expression. We also examined whether genetic alterations of EGFR
affect the antitumor action of combined treatment with nimotu-
zumab and radiation.
MATERIALS AND METHODS
Cell lines and reagents
The human NSCLC cell lines NCI-H292 (H292), NCI-H460 (H460),
Ma-1, NCI-H1299 (H1299), and NCI-H1975 (H1975) were obtained
as previously described (Okabe et al, 2007) and were maintained
under a humidified atmosphere of 5% CO2 in air at 37.01Ci n
RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented
with 10% fetal bovine serum and 1% penicillin–streptomycin.
Nimotuzumab was provided by Daiichi Sankyo Co Ltd
(Tokyo, Japan), and gefitinib was obtained from AstraZeneca
(Macclesfield, UK).
Flow cytometric analysis of surface EGFR expression
Cells (1.0 10
6) were stained for 2h at 41C with an
R-phycoerythrin-conjugated mAb to EGFR (BD Biosciences,
San Jose, CA, USA) or an isotype-matched control mAb (BD
Biosciences). The cells were washed three times before measure-
ment of fluorescence with a flow cytometer (FACScalibur; Becton
Dickinson, San Jose, CA, USA).
Immunoblot analysis
Cell lysates were fractionated by SDS-polyacrylamide gel electro-
phoresis on a 7.5% gel, and the separated proteins were transferred
to a nitrocellulose membrane. After blocking of nonspecific sites,
the membrane was incubated consecutively with primary and
secondary antibodies, and immune complexes were detected with
the use of enhanced chemiluminescence reagents, as described
previously (Okabe et al, 2007). Primary antibodies to phosphorylated
EGFR (pY1068) were obtained from Cell Signaling Technology
(Beverly, MA, USA), and those to EGFR were from Zymed (South
San Francisco, CA, USA). Horseradish peroxidase-conjugated goat
secondary antibodies were obtained from Amersham Biosciences
(Little Chalfont, UK).
Clonogenic assay
Exponentially growing cells in 25-cm
2 flasks were harvested by
exposure to trypsin and counted. They were diluted serially to
appropriate densities and plated in triplicate in 25-cm
2 flasks
containing 10ml of medium supplemented with 1% fetal bovine
serum in the absence or presence of 700nM nimotuzumab. After
incubation for 24h, the cells were exposed to various doses of
g-radiation with a
60Co irradiator at a rate of approximately
0.82Gymin
 1 and at room temperature. The cells were then
washed with phosphate-buffered saline, cultured in drug-free
medium for 10–14 days, fixed with methanol:acetic acid (10:1,
v/v), and stained with crystal violet. Colonies containing 450 cells
were counted. The surviving fraction was calculated as (mean
number of colonies)/(number of inoculated cells plating effi-
ciency). Plating efficiency was defined as the mean number of
colonies divided by the number of inoculated cells for control
cultures not exposed to nimotuzumab or radiation. The surviving
fraction for combined treatment was corrected by that for
nimotuzumab treatment alone. The dose enhancement factor was
then calculated as the dose (Gy) of radiation that yielded a
surviving fraction of 0.5 for vehicle-treated cells divided by that for
nimotuzumab-treated cells (after correction for drug toxicity).
Antitumor activity of nimotuzumab with or without
radiation in vivo
Animal experiments were performed in accordance with the
Recommendations for Handling of Laboratory Animals for
Biomedical Research, compiled by the Committee on Safety and
Ethical Handling Regulations for Laboratory Animal Experiments,
Kyoto University, and they met the requirements of the UKCCCR
guidelines (Workman et al, 1998). Tumour cells (2 10
6) were
injected subcutaneously into the right hind leg of 7-week-old
female athymic nude mice. tumour volume was determined
from caliper measurement of tumour length (L) and width (W)
according to the formula LW
2/2. Treatment was initiated when
tumours in each group achieved an average volume of approxi-
mately 170–200mm
3. Treatment groups consisted of control,
nimotuzumab alone, radiation alone, and the combination of
nimotuzumab and radiation, with each group containing seven or
eight mice. Nimotuzumab was administered intraperitoneally in a
single dose of 1.0mg per mouse; mice in the control and radiation-
alone groups were injected with vehicle (physiological saline).
Tumours in the right hind leg of mice were exposed to 10Gy of
g-radiation with a
60Co irradiator at a rate of approximately
0.32Gymin
 1 beginning 6h after drug treatment. Growth delay
(GD) was calculated as the time required for treated tumours to
achieve a fivefold increase in volume minus the corresponding
time required for control tumours. The enhancement factor was
then determined as (GDcombination–GDnimotuzumab)/(GDradiation).
RESULTS
Surface EGFR expression in NSCLC cell lines of differing
EGFR status
We first examined the surface expression of EGFR in five NSCLC
cell lines by flow cytometry. The EGFR status for the cell lines was
determined in our previous study (Okabe et al, 2007). Three cell
lines (H460, H292, and H1299) possess wild-type EGFR alleles,
whereas the other two cell lines (Ma-1 and H1975) harbour EGFR
mutations (Table 1). Ma-1 cells have an in-frame deletion in
Table 1 Characteristics of NSCLC cell lines
Cell line EGFR surface expression EGFR status
H460 Low Wild type
H292 High Wild type
H1299 Low Wild type
Ma-1 Moderate del(E746–A750)
H1975 Low L858R/T790M
EGFR¼epidermal growth factor receptor; NSCLC¼non-small cell lung cancer
Anticancer effect of nimotuzumab and ionising radiation
Y Akashi et al
750
British Journal of Cancer (2008) 98(4), 749–755 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sexon 19 (E746–A750). H1975 cells harbour the L858R mutation
in exon 21 and a secondary mutation in exon 20 (T790M).
Activating mutations in exons 19 and 21 are associated with
sensitivity to EGFR-TKIs (Lynch et al, 2004; Paez et al, 2004; Pao
et al, 2004; Cappuzzo et al, 2005; Mitsudomi et al, 2005; Takano
et al, 2005), whereas the T790M mutation contributes to the
development of resistance to these drugs (Kobayashi et al, 2005;
Pao et al, 2005). Our flow cytometric analysis demonstrated that
H292 and Ma-1 cells express high and moderate levels of EGFR on
the cell surface, respectively, whereas H460, H1299, and H1975
cells showed a low level of surface EGFR expression (Figure 1).
Effect of nimotuzumab on EGFR phosphorylation
Next, we determined whether nimotuzumab inhibits ligand-
induced EGFR phosphorylation in the five NSCLC cell lines. The
cells were deprived of serum overnight, exposed to various
concentrations of nimotuzumab, or to gefitinib, for 15min, and
then stimulated with EGF for 15min. In the NSCLC cells that
harbour wild-type EGFR (H460, H292, and H1299), phosphoryla-
tion of EGFR was undetectable in the absence of EGF, but was
markedly induced on exposure of the cells to this growth factor.
The EGF-induced phosphorylation of EGFR in these cells was
completely inhibited by the EGFR-TKI gefitinib. Nimotuzumab
also inhibited the EGF-induced EGFR phosphorylation in a
concentration-dependent manner in H292 cells (which have a
high level of surface EGFR expression), whereas it did not
substantially affect such phosphorylation in H460 or H1299 cells
(both of which have a low level of surface EGFR expression)
(Figure 2A–C). We previously showed that the basal level of EGFR
phosphorylation was increased in the EGFR mutant NSCLC cell
lines Ma-1 and H1975, indicative of constitutive activation of the
EGFR tyrosine kinase (Okabe et al, 2007). The phosphorylation of
EGFR in EGF-treated Ma-1 cells (which have a moderate level of
surface EGFR expression) was inhibited by gefitinib as well as by
nimotuzumab in a concentration-dependent manner (Figure 2D).
In contrast, the constitutive activation of EGFR in H1975 cells
(which have a low level of surface EGFR expression) was inhibited
partially by gefitinib but was unaffected by nimotuzumab
(Figure 2E). These results suggested that the inhibition of EGFR
phosphorylation by nimotuzumab may be related to the surface
expression level of EGFR rather than to the mutational status
of EGFR.
Augmentation of the cytotoxic effect of radiation in NSCLC
cells by nimotuzumab in vitro
We examined whether nimotuzumab might enhance the anticancer
effect of g-radiation in the five NSCLC cell lines with the use of a
clonogenic assay. Tumour cells were incubated with or without
nimotuzumab for 24h, exposed to various doses of g-radiation,
and then allowed to form colonies in drug-free medium for 10–14
days. Survival curves revealed that, whereas nimotuzumab had no
effect on the radiation sensitivity of H460, H1299, or H1975 cells, it
enhanced the cytotoxic effect of radiation in H292 and Ma-1 cells,
with a dose enhancement factor of 1.5 and 1.3, respectively
(Figure 3). These results showed that nimotuzumab increased the
radiosensitivity of the NSCLC cell lines with high or moderate
levels of surface EGFR expression, consistent with the inhibitory
effects of this antibody on EGFR signalling.
Augmentation of the antitumor effect of radiation in
NSCLC cells by nimotuzumab in vivo
To determine whether the nimotuzumab-induced potentiation of
the response of NSCLC cells to radiation observed in vitro might
also be apparent in vivo, we injected three of the cell lines into
nude mice to elicit the formation of solid tumours. The mice were
then treated with nimotuzumab, radiation, or both modalities.
In the H460 xenograft model, tumour growth was inhibited by
radiation alone but not by nimotuzumab alone, and the effect of
radiation was not promoted by nimotuzumab (Figure 4A). In
contrast, radiation and nimotuzumab each inhibited the growth of
tumours formed by H292 (Figure 4B) or Ma-1 (Figure 4C) cells
during the first few weeks after treatment. Thereafter, the rate of
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Figure 1 Expression of EGFR on the surface of NSCLC cells. Surface
expression of EGFR on H460 (A), H292 (B), H1299 (C), Ma-1 (D), and
H1975 (E) cells was determined by flow cytometry. Representative
histograms of cells stained with an anti-EGFR mAb (red peak) or with an
isotype-matched control mAb (black peak) are shown.
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stumour growth increased to a value similar to that seen in control
animals. Combined treatment with radiation and nimotuzumab
resulted in a substantial delay in tumour growth and subsequent
inhibition of the growth rate of H292 and Ma-1 xenografts. The
growth delay after treatment with nimotuzumab alone, radiation
alone, or both nimotuzumab and radiation was thus 27.2, 19.6, and
53.6 days, respectively, for H292 cells and 26.7, 13.0, and 78.3 days,
respectively, for Ma-1 cells (Table 2). The enhancement factor for
the effect of nimotuzumab on the efficacy of radiation was 1.3 for
H292 cells and 4.0 for Ma-1 cells, revealing the effect to be more
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Figure 2 Effect of nimotuzumab on EGFR phosphorylation in NSCLC cells. H460 (A), H292 (B), H1299 (C), Ma-1 (D), and H1975 (E) cells were
deprived of serum overnight and then incubated first for 15min in the absence or presence of the indicated concentrations of nimotuzumab or gefitinib
(10mM) and then for an additional 15min in the additional absence or presence of EGF (100ngml
 1). Cell lysates were then subjected to immunoblot
analysis with antibodies to the Tyr1068-phosphorylated form of EGFR (pEGFR) as well as with those to total EGFR.
1 AB C
E D 1
11
0.1 0.1
0.01 0.01
0.1
0.1
IR alone
IR alone
H460 H292
Ma-1 H1975
H1299
IR alone IR alone
IR+nimotuzumab
IR+nimotuzumab
IR alone
IR+nimotuzumab
IR+nimotuzumab IR+nimotuzumab
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
0.01
0.01
1
0.1
0.01
02
Radiation (Gy) Radiation (Gy) Radiation (Gy)
46
02
Radiation (Gy)
46 02
Radiation (Gy)
46
0 2 4 6 02468 1 0
Figure 3 Effect of nimotuzumab on the response of NSCLC cells to radiation in vitro. H460 (A), H292 (B), H1299 (C), Ma-1 (D), and H1975 (E) cells
were incubated with or without 700nM nimotuzumab in medium supplemented with 1% fetal bovine serum for 24h, exposed to the indicated doses of
g-radiation, and then incubated in drug-free medium supplemented with 10% serum for 10–14 days for determination of colony-forming ability. Survival
curves were generated after correction of colony formation observed for combined treatment with ionising radiation (IR) and nimotuzumab by that
apparent for treatment with nimotuzumab alone. Data are means±s.d. of triplicates from a representative experiment.
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sthan additive. No pronounced tissue damage or toxicities such as
diarrhoea or a decrease in body weight of 410% were observed in
mice in any of the four treatment groups. These results thus
suggested that nimotuzumab potentiated the antitumor activity of
radiation in H292 and Ma-1 cells in vivo as well as in vitro.
DISCUSSION
Somatic mutations in the EGFR kinase domain and EGFR
amplification have been associated with a better response to
EGFR-TKIs, such as gefitinib and erlotinib, in patients with NSCLC
(Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004; Cappuzzo et al,
2005; Mitsudomi et al, 2005; Takano et al, 2005). Given that little is
known of the relation between such EGFR alterations and the
response to treatment with anti-EGFR mAbs, we investigated the
antitumor effect of combined treatment with the anti-EGFR mAb
nimotuzumab and radiation in NSCLC cell lines of differing
EGFR status.
The antitumor effect of EGFR-specific mAbs has been thought to
result from inhibition of ligand binding to EGFR and consequent
inhibition of EGFR activation (Li et al, 2005; Marshall, 2006). We,
therefore, examined the effect of nimotuzumab on EGF-dependent
EGFR signalling. Nimotuzumab inhibited the EGF-induced or
constitutive phosphorylation of EGFR in H292 and Ma-1 cells
(with high and moderate levels of surface EGFR expression,
respectively), consistent with the mode of action of this antibody.
However, nimotuzumab did not block EGF-induced or constitutive
EGFR phosphorylation in H460, H1299, or H1975 cells (all with a
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Figure 4 Effect of nimotuzumab on the response of NSCLC cells to radiation in vivo. H460 (A), H292 (B), or Ma-1 (C) cells were injected
subcutaneously in athymic nude mice. Treatment was initiated when tumours in each group achieved an average volume of approximately 170–200mm
3.
Mice were treated with a single dose of nimotuzumab (1.0mg per mouse) intraperitoneally, a single dose of g-radiation (10Gy), or neither (control) or both
modalities, and tumour volume was determined at the indicated time points thereafter. Data are means±s.d. for seven to eight mice per group.
Table 2 Tumour growth delay in nude mice treated with nimotuzumab,
radiation, or both modalities
H460 H292 Ma-1
Treatment Days
a GD
b Days GD Days GD
Control 10.4 13.2 15.1
Nimotuzumab alone 11.8 1.4 40.4 27.2 41.8 26.7
Radiation alone 20.4 10.0 32.8 19.6 28.1 13.0
Nimotuzumab+radiation 20.5 10.1 66.8 53.6 93.4 78.3
Enhancement factor 0.86 1.3 4.0
GD¼growth delay
aTime required for xenografts in each group to achieve a fivefold
increase in volume.
bThe additional time (days) required for xenografts in each
treatment group to achieve a fivefold increase in volume relative to the
corresponding time for xenografts in the control group.
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slow level of surface EGFR expression). These observations suggest
that the inhibitory effect of nimotuzumab on EGFR signalling
depends on the expression level of EGFR on the cell surface. A
clonogenic cell survival assay revealed that nimotuzumab en-
hanced the cytotoxic effect of radiation in H292 and Ma-1 cells, but
not that in H460, H1299, or H1975 cells. These findings support the
notion that the inhibition of EGFR signalling by nimotuzumab is
responsible, at least in part, for the enhancement of the cytotoxic
effect of radiation by this antibody. Irradiation of tumour cells has
been shown to activate EGFR via ligand-independent and ligand-
dependent mechanisms, possibly accounting for radiation-induced
acceleration of tumour cell repopulation and the development of
radioresistance (Schmidt-Ullrich et al, 1997, 2003; Dent et al,
2003). Such radiation-induced activation of EGFR-dependent
processes may represent a rationale for combined treatment with
radiation and EGFR inhibitors. It remains to be determined
whether nimotuzumab is able to block radiation-induced
activation of EGFR.
Consistent with our in vitro results, we found that nimotuzumab
enhanced the antitumor effect of radiation on H292 or Ma-1 cells
in nude mice. Such enhancement was not apparent for tumours
formed by H460 cells. Nimotuzumab alone also manifested a
substantial antitumor effect for xenografts formed by H292 or
Ma-1 cells but not for those formed by H460 cells. Together these
results suggest that the efficacy of nimotuzumab monotherapy is a
prerequisite for augmentation of radioresponse by this mAb.
Nimotuzumab was previously shown to induce the regression of
A431 tumour xenografts in vivo as a result of inhibition of
both tumour cell proliferation and tumour angiogenesis
(Crombet-Ramos et al, 2002). Immunohistochemical analysis of
tumour specimens from head and neck cancer patients treated
with the combination of nimotuzumab and radiation also showed
evidence of antiproliferative and antiangiogenic effects
(Crombet et al, 2004). These observations suggest that effects of
nimotuzumab on both NSCLC cell proliferation and tumour
angiogenesis might contribute to the enhancement of the
antitumor efficacy of radiation by this antibody observed in the
present study. Enhancement of the anticancer effect of radiation by
the anti-EGFR mAb cetuximab was previously shown to be
increased by transfection of cells to upregulate the level of EGFR
expression, suggesting that potentiation of the antitumor efficacy
of radiation by anti-EGFR mAbs is related to the absolute level of
EGFR expression (Liang et al, 2003; Bonner et al, 2004). This
finding is consistent with our present results showing that
potentiation of the antitumor activity of radiation by nimotuzu-
mab was related to the level of surface EGFR expression. The
nimotuzumab-resistant cell line H460 harbours a mutant form of
KRAS (Balko et al, 2006) that has been associated with resistance to
cetuximab (Lievre et al, 2006). However, we found that nimotu-
zumab also failed to inhibit EGF-induced EGFR phosphorylation
and to enhance the cytotoxic effect of radiation in H1299 cells,
which harbour wild-type KRAS (Coldren et al, 2006). These
observations thus support the notion that a low level of
EGFR expression at the cell surface is related to resistance to
combined treatment with nimotuzumab and radiation, irrespective
of KRAS status.
We demonstrated that nimotuzumab inhibited EGFR phosphory-
lation and enhanced the antitumor effect of radiation in EGFR
mutant Ma-1 cells (with a moderate level of surface EGFR
expression) but not in EGFR-mutant H1975 cells (with a low level
of surface EGFR expression). Nimotuzumab also potentiated the
cytotoxic effect of radiation in H292 cells, which harbour wild-type
EGFR alleles and have a high level of surface EGFR expression.
These findings support the notion that EGFR mutation is not the
major determining factor for enhancement of the antitumor effect
of radiation by nimotuzumab, consistent with previous observa-
tions with cetuximab (Barber et al, 2004; Tsuchihashi et al, 2005).
However, the mechanisms underlying such enhancement of the
antitumor effect of radiation may differ between NSCLC cells
harbouring wild-type or mutant EGFR alleles. We and others have
previously shown that mutations in the tyrosine kinase domain of
EGFR are associated with increased ligand-independent tyrosine
kinase activity of EGFR (Lynch et al, 2004) and aberrant EGFR
signalling (Amann et al, 2005; Okabe et al, 2007). Given that cell-
cycle checkpoints activated by ionising radiation are defective in
EGFR-mutant NSCLC cell lines (Das et al, 2006), the constitutive
activity of EGFR in such cells may result in unchecked DNA
synthesis and in apoptosis on exposure to ionising radiation.
It is possible that these defects in EGFR-mutant cells affect
the enhancement of the antitumor efficacy of radiation by
nimotuzumab.
In summary, we have shown that nimotuzumab enhanced the
antitumor efficacy of radiation in vitro and in vivo, providing a
rationale for future clinical investigations of the therapeutic
efficacy of nimotuzumab in combination with radiotherapy. Our
data suggest that potentiation of the antitumor activity of radiation
by nimotuzumab may be related to the level of EGFR expression at
the cell surface rather than to EGFR mutation. The preselection of
patients on the basis of genetic factors that predict treatment
sensitivity or resistance may thus be required for the combination
therapy with nimotuzumab and radiation.
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